{
    "clinical_study": {
        "@rank": "35082", 
        "arm_group": {
            "arm_group_label": "Lenalidomide, dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "Lenalidomide 25mg qd d1-21 & dexamethasone 40mg qd 1-4"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this prospective study is to determine the efficacy and safety of\n      lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome."
        }, 
        "brief_title": "Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "POEMS Syndrome", 
        "condition_browse": {
            "mesh_term": "POEMS Syndrome"
        }, 
        "detailed_description": {
            "textblock": "The investigators propose to use the adverse effects as well as the need for dose reduction\n      as a criterion to judge tolerability of treatment.\n\n      The primary endpoint would be hematological response rate according to international myeloma\n      working group (IMWG) response criteria for amyloidosis and neurological response rate\n      defined by overall neuropathy limitation scale (ONLS) score.\n\n      This study expects to enroll approximately 50 subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must understand and voluntarily sign an informed consent form.\n\n          2. Older than 18 years old at the time of signing consent.\n\n          3. Meet the diagnostic criteria of POEM syndrome.\n\n          4. Must be cytotoxic treatment naive. However, previous or existing corticosteroid\n             (prednisone or dexamethasone) or intravenous immunoglobin (IVIG) therapy is allowed.\n\n          5. Women of childbearing potential must understand that the study medication could have\n             a potential teratogenic risk. They should undergo complete contraception during the\n             study period.\n\n          6. Male subjects must agree to use condoms throughout study drug therapy.\n\n        Exclusion Criteria:\n\n          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that\n             would prevent the subject from signing the informed consent form.\n\n          2. Pregnant or lactating females.\n\n          3. Any of the following laboratory abnormalities:\n\n             Absolute neutrophil count(ANC) of<1.0\u00d710E9 cell/L. Platelet count<50\u00d710E9 cell/L.\n             Renal failure requiring dialysis. Serum alanine aminotransferase (ALT) or aspartate\n             aminotransferase (AST) >3 times of the normal upper limit.\n\n          4. Prior history of malignancies, but not including basal cell carcinoma of the skin,\n             squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in\n             situ of the breast, and T1a or T1b prostate cancer.\n\n          5. Known hypersensitivity or prior history of uncontrollable side effects to\n             dexamethasone therapy.\n\n          6. Prior use of cytotoxic drugs.\n\n          7. Subjects who are unable or unwilling to undergo antithrombotic therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816620", 
            "org_study_id": "POEMS-01"
        }, 
        "intervention": {
            "arm_group_label": "Lenalidomide, dexamethasone", 
            "description": "12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 60ml/min, oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle.\nFor patients with Ccr from 30ml/min to 60ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.\nFor patients with Ccr lower than 30ml/min, oral lenalidomide 5mg once daily for days 1-21 out of a 28 cycle.\nAll the patients take Dexamethasone orally 40mg once daily for days 1-4 out of a 28 cycle.", 
            "intervention_name": "Lenalidomide, Dexamethasone", 
            "intervention_type": "Drug", 
            "other_name": "Revlimid"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Lenalidomide", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "POEMS Syndrome", 
            "lenalidomide", 
            "newly diagnosed", 
            "plasma cell disorder", 
            "Dexamethasone"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "pumch.li.jian@gmail.com", 
                "last_name": "Jian Li, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100005"
                }, 
                "name": "Peking Union Medical College Hospital"
            }, 
            "investigator": {
                "last_name": "Dao-bin Zhou, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome", 
        "overall_contact": {
            "email": "pumch.li.jian@gmail.com", 
            "last_name": "Jian Li, M.D."
        }, 
        "overall_official": [
            {
                "affiliation": "Peking Union Medical College Hospital", 
                "last_name": "Jian Li, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Peking Union Medical College Hospital", 
                "last_name": "Dao-bin Zhou, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Hematological response rate", 
                "safety_issue": "No", 
                "time_frame": "last day of the LDx treatment regimen (up to 9 months)"
            }, 
            {
                "measure": "Neurological response rate defined by ONLS score", 
                "safety_issue": "No", 
                "time_frame": "last day of the LDx treatment regimen (up to 9 months)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816620"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking Union Medical College Hospital", 
            "investigator_full_name": "Jian Li", 
            "investigator_title": "Associate professor of Hematology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "response rate of critical organs", 
                "safety_issue": "No", 
                "time_frame": "every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months"
            }, 
            {
                "measure": "Response rate of serum vascular endothelial growth factor (VEGF) level", 
                "safety_issue": "No", 
                "time_frame": "every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months"
            }, 
            {
                "measure": "Time to initial neurological response", 
                "safety_issue": "No", 
                "time_frame": "every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From date of first diagnosis until the date of death from any cause, otherwise patients will be censored in June, 2018 (up to 5 years)"
            }, 
            {
                "measure": "Relapse free survival", 
                "safety_issue": "No", 
                "time_frame": "From date of first diagnosis until the date of first documented relapse or date of death from any cause, whichever came first, otherwise patients will be censored in June, 2018 (up to 5 years)"
            }, 
            {
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "throughout the treatment and until 30 days after the administration of the last dose of a study drug"
            }, 
            {
                "measure": "time to the best neurological response", 
                "safety_issue": "No", 
                "time_frame": "every month during the first 3 months calculated from the day study started, then every 3 months in the next 9 months"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}